Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

– Initiation of Phase 1 clinical trial marks Entrada’s transition into a clinical company – – Data anticipated in the second half of 2024 – BOSTON, Sept. 21, 2023 -- Entrada...

Related Keywords

Boston ,Massachusetts ,United States ,United Kingdom ,Karla Macdonald ,Dipal Doshi ,Nasdaq ,Linkedin ,Exchange Commission ,Entrada Therapeutics Inc ,Corporate Affairs ,Endosomal Escape Vehicle ,Chief Executive Officer ,Private Securities Litigation Reform Act ,Markets ,